We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Unveils Cytokine Testing for COVID-19 Risk Stratification and Treatment Monitoring

By LabMedica International staff writers
Posted on 24 Jun 2020
Global diagnostics company Randox Laboratories (Crumlin, UK) has unveiled cytokine testing for COVID-19 risk stratification and treatment monitoring. More...


Cytokines play a vital role in the immune system and are known to be involved in the body’s response to a variety of inflammatory and infectious disease, such as COVID-19. In addition to COVID-19 risk stratification, cytokine testing has also been linked to monitoring for allergies, vascular diseases, cancer, and a range of autoimmune diseases. Randox’s test, which looks for the presence of cytokines (a type of small protein) is performed on the company’s patented Biochip Technology, which can simultaneously detect multiple analytes from a single patient sample.

Randox’s comprehensive cytokine testing menu comprises 26 different cytokines across four different biochip panels. Designed to make cost, time and resource savings for a range of diagnostic laboratories, Randox Cytokine Biochips can detect up to 12 cytokines and growth factors from a single patient sample. The fully automated and semi-automated testing platforms are available to suit all laboratory throughputs and are suitable for use with serum and plasma samples.

“Cytokine storms, which are the overstimulation of cytokines in response to infection, are a common complication of severe cases of COVID-19, and can trigger excessive, uncontrolled systemic inflammation,” said Lynsey Adams, Randox Marketing Manager. “The monitoring of cytokine proteins therefore offers a unique opportunity to identify patients who, as a result of this viral sepsis, are at risk of poor disease outcomes including pneumonitis, Acute Respiratory Distress Syndrome, respiratory failure, shock, or even organ failure. Treatment for any infection, COVID-19 included, is most effective when administered at an early stage, and so the detection of cytokine storms within COVID-19 patients could provide vitally important information that will direct the appropriate patient care pathway and facilitate improved patient outcomes.”

“The multiplex capabilities of the Randox Biochip will provide clinicians with a more comprehensive picture of the patient’s condition,” added Adams. “Compatible with our Evidence and Evidence Investigator analyzers, which are capable of processing 2960 and 2376 tests per hour respectively, Randox Cytokine Biochip panels offer a comprehensive testing method for these proteins which play such a central role in the immune system.”



Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.